Log in

NASDAQ:CORVCorrevio Pharma Stock Price, Forecast & News

0.00 (0.00 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: $0.42
50-Day Range
MA: $0.40
52-Week Range
Now: $0.42
Average Volume5.35 million shs
Market Capitalization$27.80 million
P/E RatioN/A
Dividend YieldN/A
Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.25 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CORV



Sales & Book Value

Annual Sales$32.63 million
Book Value($0.02) per share


Net Income$-35,180,000.00
Net Margins-107.81%


Market Cap$27.80 million
Next Earnings Date6/3/2020 (Estimated)

Receive CORV News and Ratings via Email

Sign-up to receive the latest news and ratings for CORV and its competitors with MarketBeat's FREE daily newsletter.

Correvio Pharma (NASDAQ:CORV) Frequently Asked Questions

How has Correvio Pharma's stock been impacted by COVID-19 (Coronavirus)?

Correvio Pharma's stock was trading at $0.3990 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CORV stock has increased by 5.3% and is now trading at $0.42. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Correvio Pharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Correvio Pharma in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Correvio Pharma.

When is Correvio Pharma's next earnings date?

Correvio Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, June 3rd 2020. View our earnings forecast for Correvio Pharma.

How were Correvio Pharma's earnings last quarter?

Correvio Pharma Corp (NASDAQ:CORV) announced its earnings results on Monday, March, 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.13) by $0.06. The business earned $11.33 million during the quarter, compared to analysts' expectations of $11.52 million. Correvio Pharma had a negative net margin of 107.81% and a negative return on equity of 2,128.82%. View Correvio Pharma's earnings history.

What price target have analysts set for CORV?

5 equities research analysts have issued twelve-month price objectives for Correvio Pharma's stock. Their forecasts range from $1.60 to $7.00. On average, they expect Correvio Pharma's stock price to reach $4.87 in the next twelve months. This suggests a possible upside of 1,058.7% from the stock's current price. View analysts' price targets for Correvio Pharma.

Has Correvio Pharma been receiving favorable news coverage?

Press coverage about CORV stock has been trending very negative recently, InfoTrie reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Correvio Pharma earned a media sentiment score of -3.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutCorrevio Pharma.

Are investors shorting Correvio Pharma?

Correvio Pharma saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 2,310,000 shares, a decrease of 38.6% from the April 30th total of 3,760,000 shares. Based on an average daily volume of 6,660,000 shares, the short-interest ratio is presently 0.3 days. Approximately 3.8% of the company's shares are short sold. View Correvio Pharma's Current Options Chain.

Who are some of Correvio Pharma's key competitors?

What other stocks do shareholders of Correvio Pharma own?

Who are Correvio Pharma's key executives?

Correvio Pharma's management team includes the following people:
  • Dr. Mark H. N. Corrigan, CEO & Director (Age 62)
  • Mr. Justin A. Renz CPA, MST, M.S.T., MBA, CFO & Pres (Age 48)
  • Ms. Sheila M. Grant, Chief Operating Officer
  • Mr. David D. McMasters, Chief Compliance Officer & Gen. Counsel (Age 61)
  • Mr. Hugues Sachot, Chief Commercial Officer

What is Correvio Pharma's stock symbol?

Correvio Pharma trades on the NASDAQ under the ticker symbol "CORV."

Who are Correvio Pharma's major shareholders?

Correvio Pharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Beryl Capital Management LLC (3.60%), Morgan Stanley (0.42%), Two Sigma Advisers LP (0.35%), UBS Group AG (0.15%), JPMorgan Chase & Co. (0.11%) and Group One Trading L.P. (0.10%).

Which institutional investors are selling Correvio Pharma stock?

CORV stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co..

Which institutional investors are buying Correvio Pharma stock?

CORV stock was bought by a variety of institutional investors in the last quarter, including Beryl Capital Management LLC, Morgan Stanley, UBS Group AG, Two Sigma Advisers LP, and Group One Trading L.P..

How do I buy shares of Correvio Pharma?

Shares of CORV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Correvio Pharma's stock price today?

One share of CORV stock can currently be purchased for approximately $0.42.

How big of a company is Correvio Pharma?

Correvio Pharma has a market capitalization of $27.80 million and generates $32.63 million in revenue each year. The company earns $-35,180,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Correvio Pharma employs 133 workers across the globe.

What is Correvio Pharma's official website?

The official website for Correvio Pharma is www.correvio.com.

How can I contact Correvio Pharma?

Correvio Pharma's mailing address is 1441 Creekside Drive 6th Floor, Vancouver A1, V6J 4S7. The company can be reached via phone at 604-677-6905 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.